Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data [CNBC]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: CNBC
Andrew Kelly | Reuters A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Pfizer made one thing clear this week: It's officially back in the obesity race. The drugmaker is laser-focused on bringing to market treatments from its $10 billion acquisition of the obesity biotech Metsera. On Tuesday, it released promising phase two trial data on one injection , called PF'3944, that's furthest along in development. The experimental drug drove solid weight loss when taken once a month in a mid-stage trial – offering early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy. That could be a boon to Pfizer after it faced several setbacks in trying to win a slice of a market dominated by weekly injections from Eli Lilly and Novo Nordisk , along with Novo's new daily pill Patients with obesit
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Trump unveils discounted drug platform claiming to cut patient costs [MSNBC.com]MSNBC.com
- Eli Lilly: Positives Outweigh The Concerns [Seeking Alpha]Seeking Alpha
- ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLYBusiness Wire
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at JPMorgan Chase & Co. from $1,150.00 to $1,300.00. They now have an "overweight" rating on the stock.MarketBeat
- Eli Lilly and Company (NYSE:LLY) was given a new $1,281.00 price target on by analysts at Truist Financial Corporation.MarketBeat
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 2/4/26 - Form 8-K
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- LLY's page on the SEC website